Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Curigliano GiuseppeGeoffrey I ShapiroRebecca S KristeleitAlbiruni R Abdul RazakStephen LeongMaria AlsinaAntonio GiordanoKaren A GelmonErica Stringer-ReasorUlka N VaishampayanMark Ross MiddletonAnthony J OlszanskiHope S RugoKenneth A KernNuzhat PathanRachelle PereaKristen J PierceSarah C MutkaZev A WainbergPublished in: British journal of cancer (2023)